Leah Sherwood

Articles by Leah Sherwood

Valeria Santini, MDMyelodysplastic Syndromes | October 24, 2024
At EHA 2024, Dr. Santini shares data on luspatercept and imetelstat in patients with MDS and anemia.
Guillermo Garcia-Manero, MDMyelodysplastic Syndromes | October 24, 2024
Dr. Garcia-Manero discusses the latest updates from the COMMANDS trial.
Melissa BadamoMyelodysplastic Syndromes | September 26, 2024
Dr. Garcia-Manero discussed luspatercept, a first-in-class drug for patients with low-risk MDS and anemia.
Leah SherwoodPrint | August 22, 2024
Dr. DeZern discusses how medicine has changed and shares some advice for early-career clinicians.
Melissa BadamoVideo Insights | July 24, 2024
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, in Houston, Texas.
Melissa BadamoVideo Insights | July 22, 2024
The foundation conducts partnerships with companies to provide funding to accelerate novel blood cancer therapies.
Melissa BadamoMyeloma | July 24, 2024
Dr. Martin highlighted research in quadruplet therapy, CAR-T therapy, and bispecific T-cell engagers.
Melissa BadamoMyelodysplastic Syndromes | July 18, 2024
The Beat AML trial has provided practice-changing insights and allows investigators to assess the potential of novel agents.
Leah SherwoodMeeting News | July 19, 2024
Acalabrutinib and zanubrutinib demonstrated better safety and efficacy outcomes when compared with ibrutinib in CLL/SLL.
Amer Zeidan, MBBS, MHSThe HemOnc Pulse Live | July 2, 2024
The expert panel discusses current issues in the use of ESAs within MDS management.
Amer Zeidan, MBBS, MHSThe HemOnc Pulse Live | July 1, 2024
In a roundtable discussion, an expert panel discussed how approval of luspatercept has affected frontline MDS treatment.
Melissa BadamoMyelofibrosis | July 1, 2024
Julie Braish, MBBCh, discusses her study on JAK2 allele burden in myelofibrosis presented at ASCO 2024.
Leah SherwoodMyelodysplastic Syndromes | June 27, 2024
The authors reported clinically meaningful responses of luspatercept treatment from patients enrolled in the COMMANDS trial.
Melissa BadamoVideo Insights | June 25, 2024
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, at the George R. Brown Convention Center in Houston, Texas.
Tycel Phillips, MDMantle Cell Lymphoma | June 25, 2024
The 15-month PFS was approximately 33% for patients who were BTK exposed and over 50% for patients who were BTK naïve.
Amer Zeidan, MBBS, MHSThe HemOnc Pulse Live | June 21, 2024
The expert panel describes how having two separate classification systems for MDS affects their clinical practices.
Amer Zeidan, MBBS, MHSThe HemOnc Pulse Live | August 29, 2024
The expert panel discusses how to explain to patients the range of MDS severities and approach lower-risk disease.
Amer Zeidan, MBBS, MHSThe HemOnc Pulse Live | June 17, 2024
The expert panel discusses molecular testing's current place in MDS evaluation and treatment decisions.
Leah SherwoodMyelofibrosis | June 17, 2024
Dr. Rampal, of Memorial Sloan Kettering Cancer Center, discusses his abstract at the EHA 2024 Congress in Madrid, Spain.
Yucai Wang, MD, PhDMantle Cell Lymphoma | June 14, 2024
After five and a half years of follow-up, rituximab maintenance significantly improved survival outcomes.